PTC Therapeutics Inc [PTCT] stock prices are up 0.19% to $52.59 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The PTCT shares have gain 1.53% over the last week, with a monthly amount glided 6.31%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
PTC Therapeutics Inc [NASDAQ: PTCT] stock has seen the most recent analyst activity on March 11, 2025, when BofA Securities upgraded its rating to a Neutral and also boosted its price target to $55 from $41. Previously, Scotiabank started tracking the stock with Sector Perform rating on March 07, 2025, and set its price target to $55. On December 13, 2024, upgrade upgraded it’s rating to Overweight and revised its price target to $67 on the stock. RBC Capital Mkts upgraded its rating to a Outperform and increased its price target to $63 on December 03, 2024. Robert W. Baird started tracking with a Outperform rating for this stock on September 04, 2024, and assigned it a price target of $44.
The stock price of PTC Therapeutics Inc [PTCT] has been fluctuating between $24.00 and $55.60 over the past year. Currently, Wall Street analysts expect the stock to reach $51.67 within the next 12 months. PTC Therapeutics Inc [NASDAQ: PTCT] shares were valued at $52.59 at the most recent close of the market. An investor can expect a potential drop of -1.75% based on the average PTCT price forecast.
Analyzing the PTCT fundamentals
The PTC Therapeutics Inc [NASDAQ:PTCT] reported sales of 806.78M for trailing twelve months, representing a drop of -30.58%. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -0.37%, Pretax Profit Margin comes in at -0.45%, and Net Profit Margin reading is -0.45%. To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is 0.36 and Total Capital is -0.26. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -2.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 51.10 points at the first support level, and at 49.60 for the second support level. However, for the 1st resistance point, the stock is sitting at 53.64, and for the 2nd resistance point, it is at 54.68.
Ratios To Look Out For
It’s worth pointing out that PTC Therapeutics Inc [NASDAQ:PTCT]’s Current Ratio is 2.35. Further, the Quick Ratio stands at 2.31, while the Cash Ratio is 1.34. Considering the valuation of this stock, the price to sales ratio is 5.14.
Transactions by insiders
Recent insider trading involved Boulding Mark Elliott, Officer, that happened on Mar 11 ’25 when 7381.0 shares were purchased. Officer, Boulding Mark Elliott completed a deal on Mar 10 ’25 to buy 68039.0 shares. Meanwhile, Director Jacobson Allan Steven sold 1230.0 shares on Mar 04 ’25.
